Loading…
Geron Corporation is projected to decline to $1.28 by 2027, a -1% move from its current price of $1.29. GERN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $1.26 | $1.29 | $1.32 | -0.02% |
| Aug 3 | $1.24 | $1.29 | $1.34 | -0.03% |
| Aug 4 | $1.23 | $1.29 | $1.35 | -0.05% |
| Aug 5 | $1.22 | $1.29 | $1.36 | -0.06% |
| Aug 6 | $1.21 | $1.29 | $1.37 | -0.08% |
| Aug 7 | $1.21 | $1.29 | $1.38 | -0.09% |
| Aug 8 | $1.20 | $1.29 | $1.38 | -0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.20 | $1.29 | $1.38 | -0.11% |
| Week 2 | $1.17 | $1.29 | $1.42 | -0.21% |
| Week 3 | $1.14 | $1.29 | $1.45 | -0.32% |
| Week 4 | $1.12 | $1.28 | $1.48 | -0.42% |
| Week 5 | $1.10 | $1.28 | $1.50 | -0.53% |
| Week 6 | $1.08 | $1.28 | $1.52 | -0.63% |
| Week 7 | $1.06 | $1.28 | $1.54 | -0.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing therapeutics products for oncology. Its product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation is a healthcare company with a stock listed under the symbol GERN. The current price is $1.34, and the market capitalization is $859.64M, with a rank of 2476.
A major floor 17.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.3% away) — a key level to hold.
The nearest ceiling, 20.9% above — a clean break opens room to run.
A major ceiling 37.2% above — clearing it would confirm fresh momentum.
Key GERN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GERN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.39 | Sell | $1.36 | Sell |
| MA 10 | $1.41 | Sell | $1.39 | Sell |
| MA 20 | $1.44 | Sell | $1.40 | Sell |
| MA 50 | $1.32 | Sell | $1.38 | Sell |
| MA 100 | $1.43 | Sell | $1.40 | Sell |
| MA 200 | $1.40 | Sell | $1.47 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.82 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -224.76 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -9.15 | Sell |
| Bollinger %B (20,2) | -0.10 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.33 | Buy |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 34.82 | Neutral |
| Momentum (10) | -0.15 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 1.34 | Sell |
| ADX (14) | 15.74 | Neutral |
| ATR (14) | 0.04 | Info |
The near-term picture is neutral. RSI14 sits at 40, while the stock trades around key moving averages—SMA50 at $1.32 and SMA200 at $1.40.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.10 | $1.29 | $1.63 | 0% | Neutral | |
| $1.02 | $1.28 | $1.69 | -1% | Neutral | |
| $1.11 | $1.43 | $1.95 | +10% | Neutral | |
| $1.08 | $1.42 | $2.00 | +10% | Neutral | |
| $1.17 | $1.57 | $2.27 | +22% | Bullish | |
| $1.43 | $1.95 | $2.87 | +51% | Bullish | |
| $1.43 | $1.99 | $3.00 | +54% | Bullish | |
| $1.43 | $2.01 | $3.08 | +56% | Bullish | |
| $1.44 | $2.06 | $3.20 | +59% | Bullish | |
| $1.42 | $2.06 | $3.25 | +60% | Bullish | |
| $1.98 | $3.07 | $5.14 | +138% | Bullish | |
| $3.35 | $5.81 | $10.64 | +351% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.10 | $1.29 | $1.57 | +0.00% |
| September 2026 | $1.08 | $1.28 | $1.55 | -0.83% |
| October 2026 | $1.07 | $1.27 | $1.56 | -0.55% |
| November 2026 | $1.09 | $1.31 | $1.62 | +2.73% |
| December 2026 | $1.09 | $1.31 | $1.63 | +0.16% |
Click any year to see its month-by-month GERN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, GERN is projected to trade between $1.10 and $1.63, averaging $1.29 — a potential gain of 0% from today's $1.29. A consolidation phase looks the most probable path here.
Geron Corporation's 2027 outlook centres on $1.28, within a $1.02 to $1.69 range. That is -1% versus the projected 2026 average. That marks a -1% change versus current levels. Price action looks broadly range-bound.
By 2028, GERN could reach as high as $1.95, with a base case around $1.43 and support toward $1.11 — roughly +10% from $1.29. A consolidation phase looks the most probable path here.
Expect GERN to range from $1.08 to $2.00 through 2029. The $1.42 average target implies a +10% move from current prices. That is -1% versus the projected 2028 average. Price action looks broadly range-bound.
The GERN price prediction for 2030 points to an average of $1.57 (low $1.17, high $2.27) — a potential gain of +22% on today's $1.29. Buyers look set to stay in control over this stretch.
In 2031, GERN is projected to trade between $1.43 and $2.87, averaging $1.95 — a potential gain of +51% from today's $1.29. That is up +24% on the projected 2030 average. Momentum favours further upside here.
Geron Corporation's 2032 outlook centres on $1.99, within a $1.43 to $3.00 range. That is up +2% on the projected 2031 average. That marks a +54% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, GERN could reach as high as $3.08, with a base case around $2.01 and support toward $1.43 — roughly +56% from $1.29. Momentum favours further upside here.
Expect GERN to range from $1.44 to $3.20 through 2034. The $2.06 average target implies a +59% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The GERN price prediction for 2035 points to an average of $2.06 (low $1.42, high $3.25) — a potential gain of +60% on today's $1.29. Momentum favours further upside here.
In 2040, GERN is projected to trade between $1.98 and $5.14, averaging $3.07 — a potential gain of +138% from today's $1.29. That is up +49% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Geron Corporation's 2050 outlook centres on $5.81, within a $3.35 to $10.64 range. That is up +89% on the projected 2040 average. That marks a +351% change versus current levels. Momentum favours further upside here.
Investing $1,000 in GERN today (≈ 775.193798 GERN) could be worth
$4,506.85
+$3,506.85 (+351%) by 2050 · US Dollar
Based on the average projected GERN price of $5.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GERNwould be worth at today's price.
$1,000 invested in GERN on Jul 31, 2025 (≈ 869.565235 GERN) would be worth
$1,121.74
+$121.74 (+12.2%) today · 1.12× · US Dollar
Based on a GERN entry price of $1.15 vs. today's $1.29.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.42 | $908.45 | -9.2% |
| 1 month ago | $1.27 | $1,015.75 | +1.6% |
| 3 months ago | $1.58 | $816.46 | -18.4% |
| 6 months ago | $1.54 | $837.66 | -16.2% |
| 1 year ago | $1.15 | $1,121.74 | +12.2% |
| All time (5.0y) ago | $1.25 | $1,032 | +3.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GERN forecast.
Our base-case forecast reaches $2.60 around 2040.
Implied market cap at $2.60: $1.67B
The multi-year forecast shows a bullish trajectory starting in the 2030s. In 2026 the min/avg/max are $1.10/$1.34/$1.70 with 0% ROI and a NEUTRAL sentiment. By 2030, the avg price is $1.72 with a max of $2.48 and a ROI of 28.5% with a BULLISH sentiment.
The forecast continues higher through 2031–2035, with 2031 avg $2.13 (max $3.14, ROI 59%), 2032 avg $2.18 (max $3.27, ROI 62.7%), 2033 avg $2.21 (max $3.38, ROI 65.2%), 2034 avg $2.28 (max $3.53, ROI 70%), and 2035 avg $2.30 (max $3.61, ROI 71.4%). In 2040 the avg rises to $3.47 (max $5.79, ROI 158.6%) with a BULLISH sentiment, and by 2050 the avg is $6.71 (max $12.25, ROI 401.1%) staying BULLISH. These figures illustrate an upside trajectory with increasing price levels over time, though they remain estimates and carry uncertainty.
Tap a question to reveal the answer.
Avg $1.72, min $1.29, max $2.48, ROI 28.5%, sentiment BULLISH.
Forecasts show NEUTRAL in 2026 and gradually higher expectations thereafter, with 2030 onward showing BULLISH sentiment and higher average/max prices. These figures are estimates, not guarantees.
In 2040, the max price forecast is $5.79.
Current price $1.34; Market cap $859.64M.
RSI14 is 40; sentiment NEUTRAL. SMA50 is $1.32, SMA200 is $1.40. The 30-day range is $1.13 to $1.59 with support at $1.23 and resistance at $1.56.
Geron Corporation Community Discussion
0Share your Geron Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.